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Abstract
After the subcutaneous injection of retinoyl L-glucuronide (RAG), both RAG and retinoic acid (RA), formed by the
hydrolysis of RAG in vivo, achieved peak plasma concentrations within 1^2 h. Thereafter, RA was rapidly cleared from the
plasma whereas RAG was eliminated much more slowly. No significant changes were noted in the peak (2 h) plasma levels of
RAG for treatment periods up to 56 days (one injection of RAG/day), in the clearance rate of RAG from plasma, or in
plasma retinol concentrations. Similarly, no consistent decrease in plasma levels of the RA hydrolysis product was observed.
Mice undergoing these long-term chronic treatments with RAG did not show any clinical manifestations of retinoid toxicity.
Taken together, our findings that chronic dosing with RAG produces sustained levels of both the parent compound and the
RA hydrolysis product, combined with the apparent low toxicity of RAG, suggest that RAG could be a safe and useful
alternative to some retinoids which are presently being utilized in the clinic. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Since the demonstration that all-trans-retinoic acid
(RA) was a highly e⁄cient compound for inducing
remission in patients with acute promyelocytic leuke-
mia [1], there has been considerable interest in the
use of retinoids for other therapeutic applications in
oncology, including Kaposi sarcoma [2], neuroblas-
toma [3], multiple myeloma [4], and head-and-neck
tumors [5]. However, two limitations in the use of
RA in the clinic are: (1) that this retinoid rapidly
induces its own metabolism during chronic treatment
by increased oxidation via the cytochrome P450
(CYP) enzyme system [6], and (2) its inherent toxic-
ity. Because of the induced metabolism of RA, plas-
ma RA concentrations are markedly reduced to al-
most undetectable levels within days of the initiation
of drug administration. As a result, co-administra-
tion of CYP inhibitors such as ketoconazole and
liarozole have been used to increase the plasma con-
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centrations of RA during long-term treatment, or
drug ‘holidays’ have been utilized to allow for return
of plasma drug clearance toward baseline levels [7,8].
This pharmacologic property of RA, its markedly
increased metabolism with chronic dosing, has con-
tributed to the limited use of this retinoid in onco-
logic applications. Indeed, there is now evidence that
relapse from RA therapy of acute promyelocytic leu-
kemia patients may, under certain circumstances, be
due to a pharmacological inability to present a sus-
tained e¡ective drug concentration to the leukemic
cells [9].
The glucuronide conjugate of retinoic acid (retino-
yl L-glucuronide; RAG) has been the subject of in-
tense interest because of its biological e¡ectiveness in
a variety of retinoid-sensitive systems, including the
induction of cellular di¡erentiation of certain tumor
cell types [10,11]. At the same time, RAG demon-
strates markedly reduced cytotoxicity and teratoge-
nicity when compared to the RA parent compound
[10]. Pharmacologic studies of RAG have indicated
that its rate of clearance was relatively slow in well
nourished animals, such that high plasma levels can
be sustained for up to 12 h after the administration
of a single subcutaneous or intravenous dose [12].
This kinetic behavior is in contrast to the rapid clear-
ance observed with RA, which is no longer detect-
able in plasma within hours following administra-
tion.
In order to assess the possible use of RAG in long-
term clinical applications, we have investigated both
its conversion to RA and possible changes in its
pharmacokinetics during chronic administration.
We now demonstrate that unlike RA, daily admin-
istration of RAG for up to 2 months does not reduce
peak plasma drug concentrations nor signi¢cantly
change plasma retinol concentrations. Our data in-
dicate that RAG can be hydrolyzed in vivo to RA
and, furthermore, that daily RAG treatment results
in peak RA plasma levels that do not decrease dur-
ing the course of long-term treatment.
2. Materials and methods
2.1. Laboratory precautions
All work with retinoids or with plasma from
RAG-treated mice was performed under dim light
to reduce photodegradation.
2.2. Chemicals and solvents
All-trans-retinoyl L-glucuronide (RAG) was syn-
thesized according to Becker et al. [13]. The purity
of RAG was determined by HPLC [14]. Methanol,
potassium acetate, acetic acid, butylated hydroxyto-
luene, anhydrous sodium sulfate, methylene chloride,
and ethyl acetate were purchased from Fisher Scien-
ti¢c Co. (Fair Lawn, NJ). All-trans-RA, retinol, and
retinyl palmitate for use as standards for HPLC were
obtained from Sigma Chemical Co. (St. Louis, MO).
2.3. HPLC
The Emory Gynecology and Obstetrics HPLC set-
up is a Knauer variable wavelength monitor con-
nected to a Rainin HPLC system, consisting of two
Rabbit HP pumps, a pressure monitor, a mixing
chamber, and a Rheodyne sample injector ¢tted
with a 2 ml sample loop. The system is controlled
from a Macintosh IIci using a Dynamax HPLC
Method Manager. Retinoids were separated on a
Varian (Rainin) 5 Wm C18 column by reversed-phase
HPLC procedure using a solvent £ow rate of 1 ml/
min as previously described [14]. For RAG and RA
determination, the column was eluted isocratically
with a solvent consisting of 13% 0.01 M potassium
acetate^87% methanol adjusted to pH 5.6 with a few
drops of acetic acid. For liver retinoids, the column
was eluted isocratically with methanol at a £ow rate
of 2 ml/min.
2.4. Mice
Harland ICR female mice were housed and main-
tained in accordance with NIH guidelines for animal
use and care under the supervision of Laboratory
Animal Resources, Emory University. They received
a standard pellet diet (Purina, St. Louis, MO) and
tap water ad libitum. At 10^12 weeks of age, mice
received either a single subcutaneous (s.c.) injection
of RAG at the indicated concentrations per kg body
weight (b.wt.) in the upper dorsum or daily s.c. in-
jections for the indicated time periods in the long-
term studies. RAG was prepared in 10% dimethyl-
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sulfoxide^90% phosphate-bu¡ered saline at stock
concentrations such that the dosing volume was al-
ways 0.1 ml. Control mice were administered the
vehicle only or were left untreated. Stock solutions
of RAG were prepared every 2 weeks, aliquoted and
frozen at 380‡C, for daily use during the long-term
chronic studies.
At the indicated time after RAG administration,
mice were anesthetized using Metofane (methoxy£ur-
ane, Mallinckrodt Veterinary, Mundelein, IL). They
were then exsanguinated until they expired by car-
diac puncture into heparinized syringes. The blood
was centrifuged for 12 min at 1200Ug at room tem-
perature and the plasma was recovered and stored at
320‡C until analyzed by HPLC.
2.5. Hepatic vitamin A
Retinoids were extracted from liver by grinding
tissue samples in methylene chloride in the presence
of anhydrous sodium sulfate as previously described
[15]. Brie£y, a small amount (100^200 mg) of liver
was added to a round-bottomed Pyrex glass tube
that contained about 200 mg of anhydrous sodium
sulfate. Methylene chloride (1 ml) was added and the
sample homogenized using a mechanical tissue grind-
er. The sample was clari¢ed by centrifugation (1500
rpm for 5 min). After the supernatant was recovered,
four further extractions were conducted with ethyl
acetate (1 ml), the supernatants sequentially pooled,
and the pool evaporated to dryness under nitrogen.
Just prior to chromatography, the residue was resus-
pended in 0.5 ml ethyl acetate.
2.6. Cell culture
The LA-N-5 human neuroblastoma cell line was
grown in RPMI 1640 medium supplemented with
10% heat-inactivated fetal calf serum, HEPES bu¡er
and 50 IU/ml penicillin/streptomycin and 1 Wg am-
photericin (complete medium), as previously de-
scribed [16]. For treatment of cells in culture, RAG
was ¢rst dissolved in dimethylsulfoxide to a concen-
tration of 5U1032 mmol and then diluted in com-
plete medium to the indicated concentrations. The
e¡ects of RAG on LA-N-5 cell proliferation was
assessed by staining of cell protein with sulforhod-
amine (SRB) as described [17].
3. Results
3.1. In vivo kinetics
The mean concentrations of RAG and all-trans-
RA found in plasma at various times during a 24 h
period after RAG administration (30 Wmol/kg b.wt.)
are shown in Fig. 1. Both RAG and RA, resulting
from the hydrolysis of RAG, reached peak plasma
concentrations of 3.2 WM and 0.27 WM, respectively,
1^2 h after administration. As shown, the RA was
rapidly cleared and was no longer detectable in the
plasma at the 4 h time point. In contrast, the elimi-
nation of RAG was much slower, still showing mi-
cromolar concentrations 8 h after the s.c. injection.
Twenty-four hours after administration, the plasma
RAG concentration had decreased close to its base-
line value. At selected time points, the presence of
RAG was con¢rmed by treating the serum with L-
glucuronidase, which then yielded RA. No attempts
were made to distinguish between trans and cis iso-
mers of the retinoids.
Fig. 1. Plasma concentration of RAG (b) and RA (F) follow-
ing a single administration of RAG. Mice were injected s.c.
with 30 Wmol/kg b.wt. of RAG, then bled by cardiac puncture
at the indicated times following the injection. Data represent
mean values þ S.D. of 3^5 mice at each time point.
BBADIS 61966 9-10-00
N. Sidell et al. / Biochimica et Biophysica Acta 1502 (2000) 264^272266
3.2. Chronic administration
All-trans-RAG was administered s.c. to mice at
half the dose (15 Wmol/kg b.wt.) given for the 24 h
kinetic study above. The mice were injected once a
day for up to 56 days. Plasma was obtained by car-
diac puncture (3^5 mice/group) 2 h after the s.c. in-
jections, which represented the time to peak plasma
concentration of RAG and RA as determined from
the 24 h kinetic study. Groups of mice were bled on
the following time schedule representing the number
of days from the initial RAG administration: 0, 1, 2,
3, 4, 7, 14, 21, 28, 42, 56. On days 0, 7, 14, 28, and 56
other groups of mice were also bled 4 h after the s.c.
RAG injections in order to assess whether a shift in
the kinetics of retinoid clearance occurred over the
course of treatment. For additional control purposes,
two groups (3 mice/group) of control mice were in-
jected with RAG along with the 56-day-treated
groups, and bled 2 and 4 h after injections. Fig. 2
demonstrates mean RAG concentrations ( þ S.D.) of
approximately 1.28 þ 0.22 WM were achieved at 2 h
throughout the 56 day treatment, whereas the mean
4 h plasma levels of RAG were 0.54 þ 0.13 WM (not
shown). The peak (2 h) plasma levels of RAG at all
times throughout the 56 day treatment period were
similar. Likewise, the plasma concentration of RAG
in the 4 h samples were consistently 30^50% of those
at 2 h at all times during this period. Retinol levels
did not change signi¢cantly during the course of this
chronic RAG treatment.
In contrast to our ¢nding that RA could be readily
found in plasma following the higher RAG dose giv-
en in the short-term 24 h kinetic analysis (Fig. 1),
RA was not consistently detected in the plasma sam-
Fig. 2. Plasma concentration of RAG (gray bar) and retinol (ROL, open bar) during long-term, chronic administration of RAG.
Mice were injected s.c. with 15 Wmol/kg b.wt. of RAG once per day for up to 56 days. Blood was obtained by cardiac puncture 2 h
following injection of RAG on the indicated day of treatment. Data represent mean values þ S.D. of 3^5 mice at each time point.
Fig. 3. Plasma concentrations of RAG (F), RA (8), and reti-
nol (ROL, O) at 2 h after the daily subcutaneous treatment of
mice with RAG (30 Wmol/kg b.wt.) for up to 12 days. Values
represent mean þ S.D. of 3^5 mice at each time point.
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ples from this 56 day study. Some samples, however,
showed RA levels near the limit of detection of our
HPLC system (V0.05 WM). There was no time-re-
lated pattern as to which plasma specimens showed
low levels of RA such that positive samples were
obtained from various mice at both the beginning
and end of the 56 day treatment. Therefore, in a
third treatment protocol, we injected RAG s.c. at
the higher dose (30 Wmol/kg b.wt.) once each day
for up to 12 days. Mice were then bled 2 h after
the RAG injections on days 0, 2, 4, 7, and 12. As
before, the mice on the last day (day 12) included a
group that had been treated continuously with RAG
for 12 days and a control group that was treated
with RAG for the ¢rst time on day 12. Fig. 3 shows
that mean plasma levels of RAG at 2 h ranged be-
tween 5.5 and 9.0 WM and that these peak levels were
not di¡erent throughout the 12 days of treatment. In
these studies, all-trans-RA was detected in all plasma
samples and ranged between 0.27 and 0.64 WM.
These 2 h plasma levels of RA did not decrease
throughout the 12 day treatment or between the
12-day-treated mice and controls. As before, the
mean endogenous plasma level of retinol
(0.80 þ 0.13 WM) was not altered during the course
of this RAG treatment protocol.
3.3. Weight gain
In the 56 day chronic administration of RAG,
there were no signi¢cant di¡erences in initial or ter-
minal weights, water consumption, social behavior,
or apparent vitality between RAG-treated and con-
trol groups. Mean weights ( þ S.D.) after 16 days of
treatment were 28.90 þ 1.15 g for controls versus
28.38 þ 1.84 g for RAG-treated (P = 0.614) and after
56 days were 31.7 þ 1.42 g for controls versus
30.55 þ 0.52 g for RAG-treated (P = 0.12) (Fig. 4).
There were no observable clinical manifestations of
retinoid toxicity in the RAG-treated group, as has
been reported in mice when chronically treated
with other retinoids (e.g. weight loss, alopecia, and
scaly skin [18].
3.4. Liver vitamin A levels
The mean ( þ S.D.) vitamin A concentration of the
56 day control group (4.79 þ 0.49 Wmol/g tissue) was
signi¢cantly higher (P6 0.005) than that of the
RAG-treated mice (3.66 þ 0.51 Wmol/g). There were
no signi¢cance di¡erences in liver weights between
these two groups of mice (not shown). In both con-
trol and RAG-treated mice, greater than 98% of hep-
atic vitamin A was stored in the form of retinyl es-
ters.
3.5. Biologic activity of RAG on human tumor cells
Our in vivo studies indicated that micromolar
blood levels of RAG can be maintained during
chronic long-term administration. To determine
whether such levels could have biological signi¢-
cance, we assessed the ability of RAG to inhibit
the growth and induce morphologic di¡erentiation
of the LA-N-5 human neuroblastoma cell line. This
cell type has been shown to be exquisitely sensitive to
di¡erentiation induction by retinoids, and neuroblas-
toma is now treated with retinoids in the clinic [3].
As shown in Fig. 5, RAG induced neurite outgrowth
from LA-N-5 cells. This e¡ect ¢rst became apparent
after about 2 days of continuous exposure in culture,
with maximal increases in the formation of neurites
occurring at RAG concentrations in the 5^10 WM
range after extended periods (s 6 days). Concentra-
tions below 0.1 WM produced no noticeable morpho-
logic e¡ects. No decrease in the percentage of viable
cells was detected in treated cultures as compared
Fig. 4. Lack of e¡ect of long-term RAG treatment on weight
gain of mice. Twelve-week-old mice were chronically injected
with RAG (b) as described in Fig. 2 and their weights com-
pared with control mice (a) on the 16th and 56th day of treat-
ment. Data represent mean þ S.D. of four mice in each group.
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with control cultures. These morphologic changes are
similar to those extensively reported after RA treat-
ment of LA-N-5 [19], with the exception that max-
imal neurite outgrowth is seen with RA at somewhat
lower concentrations (s 1 WM).
Fig. 6 shows the dose-dependent e¡ects of RAG
on the growth of LA-N-5 cells as assessed by SRB
protein staining. As seen, greater than 40% growth
inhibition was achieved at RAG concentrations
above 1 WM in these 5 day cultures, while little e¡ect
was found below 1038 M. For comparison, the
growth inhibitory e¡ects of RA were also tested in
parallel cultures. The dose^response curves indicate
that RA was 5^10-fold more potent than RAG in
inhibiting the growth of LA-N-5 cells. This greater
potency of RA versus RAG was consistent with our
morphologic observations of the relative ability of
the two compounds to induce neurite outgrowth.
4. Discussion
Nau et al. [12] reported that a single s.c. injection
of RAG (20 Wmol/kg b.wt.) into pregnant NMRI
female mice gave peak plasma concentrations at 2 h
of RAG (2.0 WM) and of RA (0.7 WM). Thereafter,
the RA concentration decreased rapidly to 0.05 WM
at 4 h, whereas the RAG concentration fell much
more slowly, e.g., 1.2 WM at 4 h and 0.40 WM at
8 h. Interestingly, when the same single dose of RA
was injected s.c. into NMRI mice, the peak plasma
concentration of RA at 1 h was only 0.1 WM, fol-
lowed by a rapid decline.
When single s.c. injections of RAG were adminis-
tered to Harland ICR female mice in our study, the
results were qualitatively similar to those of Nau et
al. [12], but quantitatively somewhat di¡erent. Both
RAG and its hydrolysis product RA peaked at 1^2 h
Fig. 6. Dose^response curves showing the e¡ects of RAG (a)
and RA (b) on LA-N-5 cell growth after 5 days of culture.
Values represent the mean þ S.D. of triplicate samples of a typi-
cal experiment and are expressed as percent of control cultures
as assessed by the SRB protein assay.
Fig. 5. Morphology of LA-N-5 neuroblastoma cells in the absence and presence of RAG. Cultures were treated for 10 days with ve-
hicle (A) or 5 WM RAG (B). Photographed under phase contrast. U150.
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followed by a relatively slow decrease in the RAG
concentration and a rapid fall in the RA concentra-
tion. The peak RAG concentration after a single
dose (30 Wmol/kg b.wt.) in our studies, however,
was approximately 1.5-fold higher than that in Nau’s
work, whereas the peak RA concentration was lower
(V0.3 WM). Thus, the ratio of peak RA/peak RAG
was 0.08 in our study and 0.35 in Nau’s. This di¡er-
ence may re£ect a more rapid hydrolysis rate of
RAG to RA in NMRI mice than in ICR mice and/
or di¡erences in the clearance rate of RA between
strains. Regarding the latter possibility, 0.05 WM RA
could be detected in the plasma of NMRI mice 4 h
after RAG injection [12] while essentially no RA
(90.01 WM) was detected in our study at the same
time point in ICR mice. Thus, the rate of conversion
of RAG to RA and possibly the rate of RA clear-
ance seem to be strain-dependent. In Sprague^Daw-
ley rats, the ratio of peak RA/peak RAG after a
single s.c. injection of RAG (20 Wmol/kg b.wt.) is
0.07, similar to that in ICR mice (A. Ueltschy and
J.A. Olson, unpublished data). Similarly, in our 12
day experiment, the mean ratio of peak RA/peak
RAG at 2 h was found to be approximately 0.06
(Fig. 3) throughout the treatment period, suggesting
that the rate of hydrolysis of RAG to RA and the
latter’s clearance remained relatively constant during
this period.
In pregnant NMRI mice, Nau et al. [12] found
that a single s.c. dose of RAG (20 Wmol/kg b.wt.)
given on gestational day 11 was more teratogenic
than the same s.c. dose of RA. In contrast, RA,
given orally or by s.c. injection on gestational day
11, is much more teratogenic than RAG in Sprague^
Dawley rats ([20], A. Ueltschy and J.A. Olson, un-
published observations). Although the relative tera-
togenicity of RA and RAG has not been examined in
Harland ICR mice, daily s.c. dosing with similar
amounts of RAG (15 Wmol and 30 Wmol/kg b.wt.)
for up to 56 days caused no toxic manifestations in
our study. NMRI mice thus seem to be much more
sensitive to both RA and RAG than other mice or
rats that have been studied.
Although blood plasma levels of RAG and its
conversion to RA following RAG administration
have been studied in a variety of species under
both vitamin A-de¢cient and -su⁄cient conditions
[12,13,20], the present work has for the ¢rst time
tested the consequences of long-term RAG treatment
on resulting retinoid plasma levels. Importantly, dai-
ly s.c. injections of RAG resulted in peak plasma
levels that did not decrease during the course of a
2 month treatment period. Thus, multiple RAG treat-
ment does not appear to induce its own metabolism,
as is the case for all-trans-RA and, to a lesser extent,
for 9-cis-RA [21]. Furthermore, when RAG was giv-
en at daily doses (30 Wmol/kg b.wt.) for 12 days,
which consistently resulted in peak plasma RA con-
centrations of about 0.5 WM, we detected no signi¢-
cant changes in RA concentrations over the 12 day
period. Thus, the production of RA from the con-
tinuous hydrolysis of persistent RAG levels appar-
ently does not result in the induction of CYP oxida-
tive enzymes [6,22] during at least the ¢rst 12 days.
The RA levels at 2 h in the 56 day study at a lower
daily dose of RAG (15 Wmol/kg b.wt.), however,
were less consistent such that further conclusions
cannot be drawn at this time.
The biological relevance of the sustained plasma
levels of RAG achieved in our study was investigated
using the retinoid-responsive LA-N-5 human neuro-
blastoma cell line. Previous work by us [19] and
others [23], has demonstrated that neuroblastoma
cells, as a group, are remarkably sensitive to reti-
noid-induced di¡erentiation both in vitro and in
vivo [3,24]. Our results suggest that the doses and
methodology of RAG administration utilized could
show clinical activity against neuroblastoma due to
the high (1^10 WM) blood levels of RAG that were
obtained, and by the fact that RA, as a hydrolysis
product of RAG, did not decrease during treatment.
It is unknown whether or not RAG itself is biolog-
ically active in neuroblastoma or other cell types, or
must be converted to RA or other active metabolites.
In this regard, previous studies have demonstrated
that RAG does not bind to RA nuclear receptors
[25], suggesting that metabolic conversion may be
required.
Plasma retinol levels did not change appreciably
during RAG administration. Although dietary or
supplemental RA can lower plasma levels of retinol
[26^30], the amounts of RA produced from RAG in
our study were apparently insu⁄cient to induce this
e¡ect. RA added to the diet of rats has also been
shown to enhance vitamin A reserves in their livers
[26,28], probably by sparing the need for vitamin A
BBADIS 61966 9-10-00
N. Sidell et al. / Biochimica et Biophysica Acta 1502 (2000) 264^272270
in peripheral tissues. The uptake of retinyl ester-con-
taining chylomicra by the liver and the release of a
retinol^retinol binding protein complex from the liv-
er seemed normal in RA-treated rats [26]. Thus, it
surprised us that long-term RAG treatment signi¢-
cantly reduced (P6 0.005) liver reserves of vitamin A
from 4.79 þ 0.49 Wmol/g to 3.66 þ 0.51 Wmol/g in our
current study. A possible explanation is that RAG is
competing with RA at regulatory sites for vitamin A
metabolism. Thus, RAG might inhibit the stimula-
tory e¡ect of RA on vitamin A uptake by intestinal
cells [31] or might o¡set the sparing e¡ect of RA on
liver reserves of vitamin A [26,28]. Clearly, the e¡ect
of RAG on liver reserves of vitamin A merits further
attention.
In conclusion, the observation that chronic subcu-
taneous dosing with RAG results in sustained ele-
vated levels of this compound may have important
therapeutic implications in clinical medicine. Pre-
vious work and our present studies have shown
that RAG can support the growth of vitamin A-de-
¢cient mice, induce the di¡erentiation of acute pro-
myelocytic leukemia and neuroblastoma cells, and
inhibit the development of prolactin-induced mam-
mary glands [10,32]. Thus, the fact that levels of
RAG in the micromolar range can be maintained
for long periods without apparent adverse side e¡ects
may well serve as an alternative to intermittent ap-
plications of RA. Furthermore, the fact that long-
term daily administration of RAG can result in
chronically elevated plasma levels of RA suggests a
more e¡ective method for delivering RA itself to
selective sites or cell types.
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